Yujun Hou, Sofie Lautrup, Stephanie Cordonnier, Yue Wang, Deborah L. Croteau, Eduardo Zavala, Yongqing Zhang, Kanako Moritoh, Jennifer F. O’Connell, Beverly A. Baptiste, Tinna V. Stevnsner, Mark P. Mattson, and Vilhelm A. Bohr
PNAS February 20, 2018 115 (8) E1876-E1885; first published February 5, 2018 https://doi.org/10.1073/pnas.1718819115
Could mice with Alzheimer’s disease introduced DNA repair deficiency, signs of neuroinflammation, decreased synaptic transmission and phosphorylated Tau pathologies improve with supplementation of Nicotinamide Riboside? The researchers saw that by supplementing with Nicotinamide Riboside there was a decrease in neuroinflammation, improved synaptic transmission and normalized DNA damage. The mice that were supplemented with Nicotinamide Riboside also showed improved memory, learning and motor function. These findings led the researchers to believe that NAD+ supplementation has therapeutic implications for humans with Alzheimer’s disease.
This article can be seen herehttps://www.pnas.org/content/115/8/E1876.short